Global Pulmonary Arterial Hypertension (PAH) Market by Drug Class and Regions — Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2020–2026

Global Pulmonary Arterial Hypertension (PAH) Market was valued at USD 6.5 Billion in 2019, and is set to grow at CAGR of 5.6% from 2020–2026. Growing cases of pulmonary arterial hypertension (PAH), increasing geriatric population, rising consumption of tobacco and alcohol, sedentary lifestyles and growing awareness regarding early diagnosis are factors driving the market.

Get Sample Report: https://dataintelo.com/request-sample/?reportId=4414

Market Trends, Drivers, Restraints, and Opportunities:

PAH is a cluster of infrequent and life-threatening ailments together recognized as pulmonary hypertension (PH).
Increasing geriatric population base with low points of immunity and high susceptibility to PAH and related ailments is a key factor that is projected to drive the growth of the market in the coming years.
Rising incidences of PAH is expected to fuel market growth.
Government support for the growth of orphan drugs is estimated to drive the market growth during the forecast period.
Patent expiration of key molecules is likely to restrain the market growth
Growing number sanction for new drugs can offer numerous opportunities for the growth of the market.